(Q43054920)

13 November 2017

title

nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study (English)

1 reference

13 November 2017

Mikhail Y Biakhov

1

1 reference

13 November 2017

Galina V Kononova

2

1 reference

13 November 2017

Jose Iglesias

3

1 reference

13 November 2017

Neil Desai

4

1 reference

13 November 2017

Paul Bhar

5

1 reference

13 November 2017

Anita N Schmid

6

1 reference

13 November 2017

Sibylle Loibl

7

1 reference

13 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Drug Safety

13 November 2017

published in

1 reference

13 November 2017

volume

9

1 reference

13 November 2017

issue

4

1 reference

13 November 2017

page(s)

515-523

1 reference

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Hypersensitivity reactions from taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Commentary: Oncologic drugs in patients with organ dysfunction: a summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2010.487063

10.1517/14740338.2010.487063

21 January 2018

Identifiers

DOI

1 reference

13 November 2017

1 reference